Abstract Objective To establish a lymphocyte line capable of long survival and expressing human NT-3 to lay a foundation for future animal and human cochlear gene transfection research. Methods We collected lymphocytes from normal human blood via Ficoll fluid and added IL-2 into the serum culture medium to promote lymphocyte growth. The NT3 cDNA was obtained by RT-PCR and ligated with the eukaryon vector which is pIRES-DsRed2 us• ing T4DNA enzyme. The NT3 cDNA gene was transfected into the lymphocyte line using cationic liposome （LP2000） . The lymphocytes transfected with NT3-cDNA were examined by RT-PCR and Western-blot methods. Results We established a new method to extend in vitro lymphocytes survival time and to transfect NT3 into lympho• cytes. The genetically engineered lymphocytes were capable of surviving over relatively long time. Positive protein signals were obtained by Western blot. Conclusions Using lymphocytes as the intermediary, recombined plasmid pIRES-DsRed2-NT3 is used to establish a lymphocyte line that expresses and secretes NT3. This cell line can be used in future animal gene cochlear transfection research and may help find an intermediary cell line for gene thera• py for human deafness.
Neurotrophic factor is very important for development and functional maintenance of the nervous system. It is closely involved in neural injury and disease. It not only plays an important role in the maintenance of normal for• mation and regulation of physiological and biochemical functions of the inner ear auditory epithelium and neu• rons during embryonic development and after birth, but also participates in protecting and restoring functions in a number of acquired disease conditions of the auditory neuron.
NT3 is a protein family composed by 774 amino acid residues which are related closely with neurological structure and function. It has been shown that NT3 has a significant protective effect for the cochlea, but it has a short half-life. The specific anatomy of the cochlea has limited the application of NT3 in the cochlea. It would be necessary to repeatedly perfuse the cochlea in order to maintain an effective concentration inside the cochlea, which would inevitably cause damage to the co• chlea. Transfection of a target gene into the cochlea therefore represents the only pathway which may pro• vide a long-term supply of the protein factor and main• tain a long-term efficacy of treatment
［1-6］
. There is no specific treatment for sensorineural hear• ing loss at present. Recent research has started to focus on gene therapy and stem cell transplantation. In both clinical and experimental research, gene transfer is an exciting new instrument, which is gaining increasing ap• plication in research on preventing and restoring senso• rineural hearing loss in recent years. Transgenic expres• sion is helpful in detecting genes playing a special role in cochlear cell biology. Such research not only increas• es understanding of the pathophysiology of deafness, but may also provide gene therapy for inner ear disease ［7, 8］ . With the progress of inner ear gene therapy study, it · · 40 has become possible to transfect a target gene into the cochlea through a gene vector, although the foreign car• rier may potentially harm the host. We chose human lymphocytes as a carrier of the intermediate host be• cause they are the major cellular components of the en• do-and perilymphatic and cerebrospinal fluid. In case genetically engineered cells die in the host body, they will be removed by the immune cells, so there will be no unknown hazards by the lymphocytes.
The purpose and the significance of this study is that a stable genetically engineered cells in the form of the normal lymphocyte that can express and secret NT3 will be useful in finding an effective way of transferring genes into the cochlea, which is the foundation for fu• ture clinical application of gene transfer therapy.
Materials and methods 1.1 Materials Human fetal liver tissues were collected from fresh liver specimen in aborted fetus. The eukary• on vector was purchased from Invitrogen Corporation, USA. Restriction enzyme EcoRI and BamHI as well as T4DNA ligase enzyme were purchased from Takara Cor• poration（Japan） . Using the human NT3 sequences in the genebank（log No, 002527） , the 5，end with a Eco• RI and BamHI restriction sites of PCR primers wsa de• signed, and the primers were synthetized by the Bioasia Corporation, Shanghai. Recombined eukaryon expres• sion vector pIRES-DsRed2-NT3 was cloned and consti• tuted in our laboratory. Human lymphocytes were ob• tained from the Nanjing Blood Center. Recombined Hu• man IL-2 was purchased from R&D Systems, USA. Li• pofectamine 2000 trasfection kit, fetal calf serum and RMPI1640 powder were purchased from the Gibco Cor• poration. NT3 antibody was purchased from the Chemi• con Corporation. The ECL LED system was purchased from the Pierce Corporation.
1.2 Methods 1.2.1 Clone of human NT3 gene The total RNA was isolated from fresh fetal liver by the Trizol method and reverse transcribed into cDNA（with random hexmer primers） . The NT3 gene was amplified by PCR with a primer at 55℃ over 30 cycles. A fragment of about 774 bp from the PCR products were isolated by electrophore• sis with 1% Agarose gel and purified by gel extraction kit. Both the purified NT3 PCR production and eukary• otic expression vector pIRES-DsRed2 were digested with EcoRI and BamHI. Then T4DNA ligase was ap• plied to the digestion mixture for 4 hours and the suc• cess of ligation was verified by gel electrophoresis and enzyme digestion.
cultivation of human lymphocyte
A Cell extraction Equal volume of concentrated white blood cell and saline was mixed and the mixture was ap• plied to Ficoll. After centrifuge for 25 min by 2500 rpm, the mononuclear cell layer （white membrane layer）was transferred by moving into a new tube.
B Cell washing The cells were washed by saline and then centrifuged for 5 min at 1500 rpm. After removing the supernatant, the cells were suspended with RM• PI1640.
C Cell culture The isolated cells were cultured with 10%FCS RMPI1640 at the cell density of 2 × 10 6 cells／ ml, with Il-2 at 37 oC, 5% CO2.
Gene transfection
Lymphocytes were transfected when cell density reached 80% . DNA-Lipofectamine 2000 complexes were prepared as following: 16 ug pIRES-DsRed2 plas• mid DNA was applied to 800 ul of growth medium with• out serum. 48 μl of Lipofectamine 2000 was diluted with 800 μl growth medium without serum and incubat• ed for 5 minutes at room temperature. Then the diluted Lipofectamine was applied to plasmid DNA. After incu• bation for 20 minutes at room temperature, the DNA-Li• pofectamine 2000 complexes were applied to cultured Lymphocytes and incubated at 37℃ in a CO2 incubator for 48 hours. Transfection was verified by examining green fluorescence under a fluorescence microscope.
1.2.4
Transfection confirmation The transfection in human lymphocytes was verified by RT-PCR.
1.2.5
Western Blot analysis Total protein from un• transfected human lymphocytes, transfected human lym• phocytes with NT3 or vector were isolated. 30 ug of pro• tein from each sample was separated by SDS -polyacryl• amide gel electrophoresis and transferred to a nitrocellu• lose membrane. After blocking with skimmed milk, an• ti-NT3 antibodies was added to the membrane and incu• bated. Then horseradish peroxidase（HRP）labeld sec• ond antibody and ECL were applied to the membrane for X-ray film exposure. Figure 1 shows the NT3-cDNA production ab• stracted from human fresh fetal liver tissue. 2.2 Sequencing the 774bp fragment coding region num• bered"2"and"3"in the NT3-cDNA coincided with the published sequence number "002"and"527" . 2.3 Figure 3 shows electrophoresis results of constitu• tion of recombined plasmid pIRES-DsRed2-NT3.
Results

１
2.4
Human lymphocytes grew well and survived at last 3 weeks on on medium containing fetal calf serum and interleukin -2（IL-2） （Figure. 4） . Figure 5 shows lym• phocytes transfected with NT-3 under a fluorescence microscope.
RT-PCR production
Following lymphocyte transfection with NT3 and PCR reaction, electrophoresis showed a 774 bp fragment, but not in cells transfected with empty vectors or in non-transfected human lymphocytes （Figure. 6） .
Western Blot analysis
There was a clear protein band in the 2nd lane（hu• man lymphocytes transfected with NT3 gene） on the NT3 has been confirmed to be an important material for maintenance of survival of auditory epithelial and au• ditory neurons by in vivo and vitro studies. it has been shown that giving NT3 protein factor through microinjec• tion or micro-osmotic pump can provide protective and therapeutic effects for sensorineural hearing loss ［2,10-12］
. However, the current administration routes are not suitable for long-term application, as maintaining a high level of expression of neurotrophic factors in the co• chlea is critical for treatment success. Cochlea is a spe• cial sensory organ. Derby and Stover injected viral vec• tors carrying a reporter gene into the guinea pig cochlea and found no change in hearing function and cochlear morphology. Gene transfer into the cochlea is consid• ered the only way to provide long-term treatments ［4,
13-14］
. The vector systems for gene transfection include viral and non-viral vector system. While the former carries relatively high transfection efficiency, its target genes in• troduce and integrate into the host DNA molecule direct• ly. Therefore, its safety remains to be determined. The advantages of non-viral vector is that it is safe and easy to conduct, although its biggest problem is the low effi• ciency of transfection.
In this study, we selected liposome LP2000 as the gene vector, which has low toxicity and high transfec• tion efficiency and expression levels in various cells. It demonstrates relative high transfection efficiency under both serum and non-serum conditions
［4］
. At the same time we choose lymphocytes as the host cell for target genes to express and secrete transfected genes. Such studies usually involve in vitro experiments because human lymphocytes can be cultured in less than 1 week. We have established experimental condi• tions that allow us to maintain lymphocytes for 3 weeks while retaining biological activity. And we continue to search for favorable experimental conditions to increase the life cycle of lymphocytes. The current study shows that human lymphocytes transfected with pIRES-DsRed2-NT3 could survive under experimental . Estab• lishing a genetically engineered lymphocyte line may be a safe and effective approach to gene therapy for sensori• neural hearing loss.
In this study, our goal is to produce biologically ac• tive NT3-engineered cells using primary cultured hu• man lymphocytes as the transfection target. Our results show that this is feasible and the resultant cells are ca• pable of expressing NT3 and biologically active. This work has laid the foundation for future animal studies.
For future research, we plan to build genetically engi• neered lymphocytes in guinea pigs, transplant the cells into the cochlea, and study effects of transplanted cells on hearing improvement and corresponding morphologi• cal changes in guinea pigs with hearing loss.as well as on cochlear homeostasis. We can assume boldly that it is not impossible to transplante human autologous genet• ically engineered lymphocytes to treat hearing impair• ment in the future.
